4,394 Shares in Eli Lilly and Company $LLY Purchased by Exane Asset Management

Key Points

• Exane Asset Management has acquired a new stake in Eli Lilly and Company, purchasing 4,394 shares valued at approximately $3.4 million, making it the fund's 14th largest holding.
• Insider trading activity includes Director J Erik Fyrwald buying 1,565 shares for over $1 million, increasing their ownership by 2.14%.
• Wall Street analysts downgraded Eli Lilly from a "strong-buy" to a "buy" rating, with a consensus price target now at $939.61 after several adjustments from various research firms.

Exane Asset Management bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 4,394 shares of the company's stock, valued at approximately $3,425,000. Eli Lilly and Company makes up approximately 1.4% of Exane Asset Management's portfolio, making the stock its 14th biggest holding.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Ables Iannone Moore & Associates Inc. increased its position in shares of Eli Lilly and Company by 10.4% during the first quarter. Ables Iannone Moore & Associates Inc. now owns 1,286 shares of the company's stock worth $1,062,000 after acquiring an additional 121 shares during the period. Cerro Pacific Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company by 2.2% in the first quarter. Cerro Pacific Wealth Advisors LLC now owns 3,319 shares of the company's stock valued at $2,562,000 after acquiring an additional 71 shares in the last quarter. Finally, Peoples Bank KS purchased a new position in Eli Lilly and Company in the first quarter valued at $204,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. JPMorgan Chase & Co. cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Finally, Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a research report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Trading Up 1.4%

Shares of Eli Lilly and Company stock opened at $724.73 on Monday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a fifty day simple moving average of $734.15 and a 200-day simple moving average of $766.60. The stock has a market cap of $685.93 billion, a price-to-earnings ratio of 47.37, a PEG ratio of 1.01 and a beta of 0.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the business earned $3.92 EPS. Eli Lilly and Company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.